CClinicalTrials.gg
CompletedNCT03422900GlyENStrokeUpdated Sep 19, 2024

Hyperglycemia in Patients with Stroke and Indication of Enteral Nutrition

An interventional study of Diabetes-Specific enteral formula and Standard formula in Hyperglycaemia (Non Diabetic), Enteral Feeding Intolerance and Stroke, sponsored by Endocrinology and Clinical Nutrition Research Center, Spain. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Endocrinology and Clinical Nutrition Research Center, Spain · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of a specific nutritional formula for diabetics on the development of hyperglycemia in patients with recent non-diabetic stroke who require admission and enteral nutritional support by nasogastric tube. As well as the effect on metabolic control, development of comorbidities, hospital stay, readmissions, mortality and tolerance of the formula under study.

Read the detailed description

MAIN GOAL:

To evaluate the effect on the development of hyperglycemia diagnosed as glycemia> 126 mg / dl on an empty stomach or> 150 mg / dl during the infusion of enteral nutrition determined by capillary glycemia during the admission of a specific formula in patients with a first episode of ischemic stroke or hemorrhagic entry into the non-diabetic HCUV stroke unit requiring enteral nutrition by nasogastric tube.

02

Conditions studied

  • Hyperglycaemia (Non Diabetic)
  • Enteral Feeding Intolerance
  • Stroke
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Admitted for a first episode of ischemic or hemorrhagic stroke.
  • Requiring total enteral nutrition by tube for at least 7 days

Exclusion criteria

Exclusion Criteria:

  • Contraindication to enteral nutrition
  • Diabetes Mellitus
  • Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting, abdominal pain
  • Need for admission to the ICU
  • Previous neurodegenerative disease
  • Antibiotherapy for 7 days prior to the inclusion visit
  • Allergies or intolerances to any of the components of the formula under study
  • Pregnant patients
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Specific Diabetes Formula

    Diabetes-Specific Enteral Formula: * Caloric density: 1,0 kcal/ml * Energy: 100 kcal * Carbohydrates: 10,1 g/100 ml; * Fat: 4,5 g/100 ml * Prot: 3,8 g/100 ml * Osmolarity: 345 mOsm/l * Fiber: 1,78 g/100 ml (80% soluble; 20% insoluble).

    Dietary Supplement: Diabetes-Specific enteral formula

  • Active comparator
    Standard Formula

    Standard Enteral Formula: * Caloric density: 1,0 kcal/ml * Energy: 100 kcal * Carbohydrates: 13,8 g/100 ml; * Fat: 3,4 g/100 ml * Prot: 3,8 g/100 ml * Osmolarity: 220 mOsm/l * Fiber: 0 g/100 ml

    Dietary Supplement: Standard formula

Interventions

  • Dietary supplementDiabetes-Specific enteral formula

    Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)

    Also known as: DIABA

  • Dietary supplementStandard formula

    Complete enteral formula normocaloric hormoproteic without fiber

    Also known as: Fresubin Original

05

What researchers measure

Primary outcomes

  1. HYPERGLUCEMIA POST-ENTERAL NUTRITION

    Glycemia over 150 mg / dl after the beginning of infusion of complete enteral. nutrition determined by capillary glycemia during admission. Dicotomic variable (Yes/No)

    Time frame: 2 WEEKS

Secondary outcomes

  1. MORTALITY

    Mortality during study period. Dicotomic variable (Yes/No)

    Time frame: 3 months

  2. ORAL FEEDING RECOVERY

    Recovery of oral feeding (More than 75% of energy needs) and withdrawal of nasogastric tube during admission. Dicotomic variable (Yes/No)

    Time frame: 3 months

06

Study locations

1 site
  • Clinic Universitary Hospital
    Valladolid, 47003, Spain
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03422900
Lead sponsor
Endocrinology and Clinical Nutrition Research Center, Spain
Responsible party
Daniel de Luis Roman (Profesor Doctor, Endocrinology and Clinical Nutrition Research Center, Spain) — Principal investigator
First posted
Feb 6, 2018
Start date
Dec 12, 2017
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Last update
Sep 19, 2024

Study contacts

Daniel A De Luis Román, Prof. Dr.
study director · Service of Endocrinology and Nutrition. Clinic Hospital University of Valladolid
Juan J López-Gómez, Prof. Dr.
principal investigator · Service of Endocrinology and Nutrition. Clinic Hospital University of Valladolid
Javier F Arenillas-Lara, Prof. Dr.
study chair · Service of Neurology. Clinic Hospital University of Valladolid

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion